"We've been banging on a wall with a bunch of drugs, and we finally put a big crack in the wall," said Dr. Jerry Wolinsky
, professor emeritus at the University of Texas in Houston. Wolinsky was a lead author on a study in January
showing that the drug, ocrelizumab, slowed the decline in patients with primary progressive multiple sclerosis.
Multiple sclerosis is a neurological disease that affects hundreds of thousands of people, mostly women, in the United States. The disease scars nerve tissue and causes a range of symptoms, from vision problems to paralysis. While the most common form of the disease gets better and worse over time, about 10% to 15%
of patients have a form known as primary progressive, which gets slowly worse over time. There had been no approved drugs for this variation until now.
"The drug is so much more effective at shutting down inflammation," said Dr. David Hafler
, a multiple sclerosis researcher and the chair of neurology at Yale School of Medicine.
Hafler has studied the drug but was not involved in the trials leading up to the FDA approval. He does not receive consulting fees from the drug's manufacturer, Genentech, but his lab has received partial funding from the company to study how the drug works.
The drug, known commercially as Ocrevus, is an infusion given every six months. It works by stamping out a class of immune cell, known as B cells, thought to play a major role in the disease. This development shifts the focus from the other therapies on the market, which have focused on T cells and have been largely ineffective at treating primary progressive multiple sclerosis.
The drug will be available "within two weeks," per Genentech
, at list price is $65,000 per year, which is on par with other drugs that treat the more common form of the disease. A 2015 study
showed that first-generation drugs that once cost $8,000 to $11,000 per year rose to roughly $60,000 per year.
Hafler expects that the price will please insurers and make the drug more widely available to all multiple sclerosis patients than had the cost been higher.
The National Multiple Sclerosis Society applauded the $65,000 price tag.
"We encourage other companies to follow suit, creating a drug pricing trend that keeps patients first," Cyndi Zagieboylo, the organization's president, said in a statement.
"The continually escalating prices of MS disease-modifying therapies are creating barriers to people with MS getting these life-changing medications," she said.
Ocrelizumab is also approved for the more common, relapsing form of multiple sclerosis. Another study in January
found that patients relapsed half as often using Ocrevus than they did using a more costly drug on the market.
That finding, Hafler said, "just knocks your socks off." However, the impact on the severe form, he said, was far more modest.
While Wolinsky said it is "a big deal" to finally have an approved drug to slow the disease, he also said that primary progressive patients would not see it as a wonder drug, either.
"I have to tell them, 'You're not necessarily going to throw away your wheelchair.' " he said.
Still uncertain, said Wolinsky, was what long-term side effects would emerge down the line.
"The drug looks to be incredibly safe for its efficacy," he said. "Now the problem, to qualify things, is that natalizumab looked that way when it was approved."
Natalizumab, which was FDA approved to treat multiple sclerosis in 2004, was found to carry a small risk for a nerve-damaging virus.
"Time will tell whether other things will emerge," said Wolinsky.